📣 VC round data is live. Check it out!
- Public Comps
- Elutia
Elutia Valuation Multiples
Discover revenue and EBITDA valuation multiples for Elutia and similar public comparables like Biohit, Mentice, OssDsign, Sensus Healthcare and more.
Elutia Overview
About Elutia
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women’s Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.
Founded
2015
HQ

Employees
51
Website
Financials (LTM)
EV
$22M
Valuation Multiples
Start free trialElutia Financials
Elutia reported last 12-month revenue of $12M and negative EBITDA of ($14M).
In the same LTM period, Elutia generated $7M in gross profit, ($14M) in EBITDA losses, and $20M in net income.
Revenue (LTM)
Elutia P&L
In the most recent fiscal year, Elutia reported revenue of $12M and EBITDA of ($13M).
Elutia is profitable as of last fiscal year, with gross margin of 54%, EBITDA margin of (104%), and net margin of 434%.
Financial data powered by Morningstar, Inc.
Elutia Stock Performance
Elutia has current market cap of $46M, and enterprise value of $22M.
Market Cap Evolution
Elutia's stock price is $1.04.
Elutia share price decreased by 10.7% in the last 30 days, and by 47.5% in the last year.
Elutia has an EPS (earnings per share) of $1.21.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $22M | $46M | -1.0% | -10.7% | -6.1% | -47.5% | $1.21 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialElutia Valuation Multiples
Elutia trades at 1.8x EV/Revenue multiple, and (1.5x) EV/EBITDA.
EV / Revenue (LTM)
Elutia Financial Valuation Multiples
As of June 3, 2026, Elutia has market cap of $46M and EV of $22M.
Elutia has a P/E ratio of 2.3x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Elutia Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Elutia Margins & Growth Rates
Elutia decreased revenue by 2% but EBITDA grew by 23% in the last fiscal year.
In the most recent fiscal year, Elutia reported gross margin of 54%, EBITDA margin of (104%), and net margin of 434%.
Elutia Margins
Elutia Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Elutia Operational KPIs
Elutia's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.5M for the same period.
Elutia's Rule of 40 is (134%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Elutia's Rule of X is (138%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Elutia Competitors
Elutia competitors include Biohit, Mentice, OssDsign, Sensus Healthcare, InspireMD, Accuray, Baumer, HeartBeam, Nutriband and Nortech Systems.
Most Elutia public comparables operate across Medical Devices, BioTech, DeepTech, FemTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 2.3x | - | 10.9x | - | |||
| 1.3x | 1.3x | 87.0x | 31.3x | |||
| 1.3x | 1.4x | (6.5x) | (5.9x) | |||
| 1.1x | 1.1x | (3.0x) | (2.9x) | |||
| 1.0x | 0.9x | (0.2x) | (0.2x) | |||
| 0.4x | 0.5x | 6.8x | 63.8x | |||
| 0.8x | - | 3.7x | - | |||
| - | 113.1x | (2.2x) | - | |||
This data is available for Pro users. Sign up to see all Elutia competitors and their valuation data. Start Free Trial | ||||||
Elutia VC Funding History
Before going public, Elutia raised $30M in total equity funding, across 4 rounds.
Elutia Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Elutia
| When was Elutia founded? | Elutia was founded in 2015. |
| Where is Elutia headquartered? | Elutia is headquartered in United States. |
| How many employees does Elutia have? | As of today, Elutia has over 51 employees. |
| Who is the CEO of Elutia? | Elutia's CEO is C. Randal Mills. |
| Is Elutia publicly listed? | Yes, Elutia is a public company listed on Nasdaq. |
| What is the stock symbol of Elutia? | Elutia trades under ELUT ticker. |
| When did Elutia go public? | Elutia went public in 2020. |
| Who are competitors of Elutia? | Elutia main competitors include Biohit, Mentice, OssDsign, Sensus Healthcare, InspireMD, Accuray, Baumer, HeartBeam, Nutriband, Nortech Systems. |
| What is the current market cap of Elutia? | Elutia's current market cap is $46M. |
| What is the current revenue of Elutia? | Elutia's last 12 months revenue is $12M. |
| What is the current revenue growth of Elutia? | Elutia revenue growth (NTM/LTM) is 2%. |
| What is the current EV/Revenue multiple of Elutia? | Current revenue multiple of Elutia is 1.8x. |
| Is Elutia profitable? | No, Elutia is not profitable. |
| What is the current EBITDA of Elutia? | Elutia has negative EBITDA and is not profitable. |
| What is Elutia's EBITDA margin? | Elutia's last 12 months EBITDA margin is (116%). |
| What is the current EV/EBITDA multiple of Elutia? | Current EBITDA multiple of Elutia is (1.5x). |
| How many companies Elutia has acquired to date? | Elutia hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Elutia has invested to date? | Elutia hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Elutia
Lists including Elutia
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.